Prognostic value of IRF-2 expression in colorectal cancer
Metrics: PDF 1010 views | HTML 1462 views | ?
Zubing Mei1,2, Guanghui Wang1,2, Zhonglin Liang1,2, Ang Cui1,2, Andong Xu3, Yun Liu1,2, Chenying Liu1,2, Yili Yang1,2, Long Cui1,2
1Department of Colorectal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Shanghai Colorectal Cancer Research Center, Shanghai, China
3Department of General Surgery, Second Affiliated Hospital to Yangzhou University School of Medicine, Yangzhou, Jiangsu Province, China
Long Cui, email: email@example.com
Keywords: colorectal cancer, interferon regulatory factor 2, prognosis, survival
Received: March 16, 2017 Accepted: April 07, 2017 Published: April 17, 2017
Interferon regulatory factor 2 (IRF-2) is known to play a pivotal role in the development and progression of several malignancies. As a crucial member of interferon regulatory factor family, the association between the expression of IRF-2 and clinical prognostic significance has not been fully explored in colorectal cancer (CRC). The purpose of our study was to investigate the expression profile of IRF-2 in CRC and to examine its association with clinical features. The expression levels of IRF-2 in 18 paired CRC and non-cancerous colorectal tissues were measured by quantitative real-time PCR (qRT-PCR) and those in 4 paired samples by Western blotting. The results showed a significant increase in IRF-2 mRNA expression and protein expression in CRC tissues compared to those in paired normal tissues. Besides, high expression of IRF-2 was significantly associated with distant metastasis (P = 0.041) and preoperative serum CEA level (P = 0.045). Kaplan–Meier survival analysis showed that patients with high expression of IRF-2 had a significantly worse overall survival than those with low expression of IRF-2 (P = 0.006). Further multivariate analysis indicated that IRF-2 and TNM stage were independent prognostic factors for overall survival in patients with CRC. Our study primarily suggests IRF-2 as a potential prognostic biomarker in CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.